Associate Professor Bengt Furberg, M.D., Ph.D., New VP Medical Affairs at Artimplant.

VASTRA FROLUNDA, Sweden -- The biomaterials company Artimplant (STO:ARTIB), engages Associate Professor Bengt Furberg, M.D., Ph.D., as Vice President Medical Affairs, effective immediately. Furberg is a physician, scientist and writer. In addition to Artimplant he has assignments in Bactiguard AB and a number of board positions.

Furberg has a wide-ranging medical background and has published some 40 articles, among others in sports medicine and clinical trials, an area in which he also writes educational literature. Moreover, Furberg has worked as a medical professional, both as head of a department of clinical physiology and as head of an occupational health centre. In addition he has long experience from the industry. For ten years Furberg was medical director of GlaxoWellcome Sweden and his latest assignment was as medical director of Bactiguard AB. He has many years experience of international requirements for obtaining regulatory clearances within pharmaceuticals and medical devices.

Hans Rosen, the CEO of Artimplant, says;

"We are pleased to have Bengt Furberg as Vice President Medical Affairs at Artimplant. Artimplant's strategy is to develop and market medical applications based on the Company's unique biomaterial Artelon[R]. Bengt Furberg will have a major influence in that process based on his medical knowledge and well-reputed experience of clinical trials and regulatory bodies. He has considerably contributed to the success of the companies where he has been operational."

About Artimplant

Artimplant restores health by offering degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[R], meet unmet clinical needs in a growing number of therapy areas. Our motto is "Help the body to heal".

Artimplant is a public company listed on the Nordic Exchange.

Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This information was brought to you by Waymaker http://www.waymaker.net